Sanofi

This sponsor has funded 58 studies across 48 countries.

PAS funded by this sponsor.
EU PAS ID Status Title Protocol uploaded Results uploaded
2333 Finalised Yes Yes
2480 Finalised No No
2679 Finalised Yes No
2999 Finalised No Yes
3025 Finalised Yes Yes
3105 Finalised Yes No
3351 Finalised No No
4062 Finalised No Yes
4242 Finalised Yes Yes
4836 Finalised Yes Yes
5094 Finalised Yes Yes
5365 Finalised Yes Yes
5602 Finalised Yes Yes
7346 Ongoing No No
9678 Finalised No Yes
10391 Finalised Yes Yes
10872 Finalised Yes No
11634 Finalised Yes Yes
11650 Finalised Yes Yes
11765 Finalised Yes Yes
12423 Finalised Yes Yes
13205 Finalised Yes No
17065 Ongoing No No
17314 Finalised Yes Yes
18153 Finalised Yes Yes
19610 Finalised Yes Yes
19769 Ongoing Yes Yes
19826 Finalised No Yes
21314 Finalised Yes Yes
23920 Finalised Yes Yes
25203 Ongoing Yes No
27883 Ongoing Yes No
28596 Finalised Yes Yes
29415 Ongoing No No
31013 Finalised Yes Yes
31210 Ongoing No No
31883 Finalised Yes Yes
35468 Ongoing No No
35547 Finalised Yes Yes
35552 Finalised Yes Yes
37342 Planned No No
38093 Ongoing No No
39096 Ongoing No No
41565 Ongoing No No
41963 Ongoing No No
42461 Finalised No Yes
43819 Ongoing No No
43837 Ongoing No No
43864 Ongoing No No
46988 Ongoing No No
47664 Planned Yes No
49201 Ongoing No No
50220 Ongoing No No
50650 Ongoing No No
50782 Ongoing No No
103426 Ongoing No No
105374 Ongoing No No
107472 Planned No No

PAS by Risk Management Plan (RMP) requirement

Sanofi

The RMP for a medical product outlines strategies to identify, assess, and mitigate risks, including PAS for further evaluation.

Category 1 studies are imposed as condition of marketing authorisation.
Category 2 studies are imposed as specific obligation of marketing authorisation.
Category 3 studies are required under other circumstances.